Bill 119 HR 1405, also known as the Pharmaceutical Manufacturing Modernization Act, aims to address the regulatory barriers that hinder the growth and establishment of new pharmaceutical manufacturing facilities in the United States. The bill directs the Comptroller General of the United States to conduct a comprehensive study to identify and assess these key regulatory obstacles. The study will focus on understanding the specific regulations and policies that create challenges for pharmaceutical companies looking to expand or build new manufacturing facilities in the US. By identifying these barriers, lawmakers hope to develop targeted solutions that will streamline the regulatory process and encourage investment in domestic pharmaceutical manufacturing. In addition to assessing regulatory barriers, the bill also aims to explore other factors that may impact the competitiveness of the US pharmaceutical manufacturing industry. This includes examining the availability of skilled labor, infrastructure needs, and potential incentives that could attract pharmaceutical companies to invest in domestic production. Overall, the Pharmaceutical Manufacturing Modernization Act seeks to promote the growth of the pharmaceutical manufacturing sector in the US by addressing regulatory challenges and identifying opportunities for improvement. By conducting a thorough study of these issues, lawmakers hope to develop policies that will support the expansion and siting of new pharmaceutical manufacturing facilities, ultimately benefiting both the industry and consumers.
Bill 119 HR 1405, also known as the Pharmaceutical Manufacturing Modernization Act, aims to address the regulatory barriers that hinder the growth and establishment of new pharmaceutical manufacturing facilities in the United...